Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Tara C Gangadhar, MD

Tara C Gangadhar, MD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
3400 Civic Center Blvd.
South Pavilion, 7th Floor
Philadelphia, PA 19104
Office: 215-662-7907
Fax: 215-662-4646
Education:
BA (Anthropology)
Columbia University, 2000.
MD (Internal Medicine)
New York University School of Medicine, 2004.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Description of Clinical Expertise

Melanoma
Cutaneous malignancies
Gastroinitestinal malignancies

Description of Research Expertise

Melanoma
Immune therpay
Targeted therapy
Phase I trials
Combination therapy
Experimental therapeutics
Pharmacology

Selected Publications

Sholl Lynette M, Andea Aleodor, Bridge Julia A, Cheng Liang, Davies Michael A, Ehteshami Mani, Gangadhar Tara C, Kamel-Reid Suzanne, Lazar Alexander, Raparia Kirtee, Siroy Alan, Watson Kimberly L: Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. Archives of pathology & laboratory medicine Sep 2015.

Ribas Antoni, Puzanov Igor, Dummer Reinhard, Schadendorf Dirk, Hamid Omid, Robert Caroline, Hodi F Stephen, Schachter Jacob, Pavlick Anna C, Lewis Karl D, Cranmer Lee D, Blank Christian U, O'Day Steven J, Ascierto Paolo A, Salama April K S, Margolin Kim A, Loquai Carmen, Eigentler Thomas K, Gangadhar Tara C, Carlino Matteo S, Agarwala Sanjiv S, Moschos Stergios J, Sosman Jeffrey A, Goldinger Simone M, Shapira-Frommer Ronnie, Gonzalez Rene, Kirkwood John M, Wolchok Jedd D, Eggermont Alexander, Li Xiaoyun Nicole, Zhou Wei, Zernhelt Adriane M, Lis Joy, Ebbinghaus Scot, Kang S Peter, Daud Adil: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology 16(8): 908-18, Aug 2015.

Gangadhar Tara C, Schuchter Lynn M: Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA oncology 1(4): 427-8, Jul 2015.

Robert Caroline, Schachter Jacob, Long Georgina V, Arance Ana, Grob Jean Jacques, Mortier Laurent, Daud Adil, Carlino Matteo S, McNeil Catriona, Lotem Michal, Larkin James, Lorigan Paul, Neyns Bart, Blank Christian U, Hamid Omid, Mateus Christine, Shapira-Frommer Ronnie, Kosh Michele, Zhou Honghong, Ibrahim Nageatte, Ebbinghaus Scot, Ribas Antoni: Pembrolizumab versus Ipilimumab in Advanced Melanoma. The New England journal of medicine 372(26): 2521-32, Jun 2015.

Twyman-Saint Victor Christina, Rech Andrew J, Maity Amit, Rengan Ramesh, Pauken Kristen E, Stelekati Erietta, Benci Joseph L, Xu Bihui, Dada Hannah, Odorizzi Pamela M, Herati Ramin S, Mansfield Kathleen D, Patsch Dana, Amaravadi Ravi K, Schuchter Lynn M, Ishwaran Hemant, Mick Rosemarie, Pryma Daniel A, Xu Xiaowei, Feldman Michael D, Gangadhar Tara C, Hahn Stephen M, Wherry E John, Vonderheide Robert H, Minn Andy J: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547): 373-7, Apr 2015.

Wang Tao, Xiao Min, Ge Yingbin, Krepler Clemens, Belser Eric, Lopez-Coral Alfonso, Xu Xiaowei, Zhang Gao, Azuma Rikka, Liu Qin, Liu Rui, Li Ling, Amaravadi Ravi K, Xu Wei, Karakousis Giorgos, Gangadhar Tara C, Schuchter Lynn M, Lieu Melissa, Khare Sanika, Halloran Molly B, Herlyn Meenhard, Kaufman Russel E: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical cancer research : an official journal of the American Association for Cancer Research 21(7): 1652-64, Apr 2015.

Gangadhar Tara C, Salama April Ks: Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets and therapy 8: 929-37, 2015.

Robert Caroline, Ribas Antoni, Wolchok Jedd D, Hodi F Stephen, Hamid Omid, Kefford Richard, Weber Jeffrey S, Joshua Anthony M, Hwu Wen-Jen, Gangadhar Tara C, Patnaik Amita, Dronca Roxana, Zarour Hassane, Joseph Richard W, Boasberg Peter, Chmielowski Bartosz, Mateus Christine, Postow Michael A, Gergich Kevin, Elassaiss-Schaap Jeroen, Li Xiaoyun Nicole, Iannone Robert, Ebbinghaus Scot W, Kang S Peter, Daud Adil: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948): 1109-17, Sep 2014.

Braunstein Inbal, Gangadhar Tara C, Elenitsas Rosalie, Chu Emily Y: Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption. Journal of Cutaneous Pathology Jun 2014.

Gangadhar Tara C, Vonderheide Robert H: Mitigating the toxic effects of anticancer immunotherapy. Nature Reviews Clinical Oncology 11(2): 91-9, Feb 2014.

back to top
Last updated: 11/13/2015
The Trustees of the University of Pennsylvania